Among them, recombinant human Nerve Growth Factor (NGF) eye drops, have been the focus of many developments in this field but have only been approved to treat corneal ulcers (Cenegermin OxervateTM) (Ahuja et al., 2020) (Tirassa et al., 2018). This evidence concerns the gene NGF and corneal infection.